Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Avalo Therapeutics (AVTX) over the last 7 years, with Q3 2025 value amounting to $14.0 million.

  • Avalo Therapeutics' Shares Outstanding (Weighted Average) rose 15243.06% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 15243.06%. This contributed to the annual value of $34.8 million for FY2018, which is 8888.43% up from last year.
  • Avalo Therapeutics' Shares Outstanding (Weighted Average) amounted to $14.0 million in Q3 2025, which was up 15243.06% from $10.8 million recorded in Q2 2025.
  • Avalo Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $14.0 million during Q3 2025, with a 5-year trough of $859381.0 in Q1 2024.